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Drug resistance remains as a major problem and a daunting challenge to successful anti-
cancer treatment. Cancer cells are masters of adaptation. Novel drugs that attack cancer in 
new ways and target key drivers of cancer cell growth are, therefore, urgently needed. At the 
same time, the more genetically stable cells of the tumor microenvironment are being 
recognized as important players in tumor development that can confer resistance to anti-
cancer drugs. Increasing attention is being paid to the tumor microenvironment, including 
cancer-associated fibroblasts (CAFs). Furthermore, the tumor suppressor gene TP53, which 
codes for the p53 protein, plays an important role in tumor suppression and cellular stress 
responses to DNA damage and anti-cancer agents. For this reason, the TP53 gene is 
frequently mutated in cancer. In the absence of mutations, the p53 protein is often 
downregulated or inactivated through other mechanisms. 
This thesis aims to elucidate pathways or mechanisms that contribute to CAF-mediated drug 
resistance in prostate cancer. The thesis is also focused on investigating a combinatorial 
therapeutic strategy to improve the effectiveness of the mutant p53-reactivating compound 
APR-246. 
The studies in paper I and II revealed that CAFs can enhance cell survival, and affect the 
sensitivity of prostate cancer cells carrying wild type p53 to chemotherapeutic drugs through 
different mechanisms. In the paper I, we showed that glutathione, produced by CAFs, 
protects cancer cells from drug-induced oxidative stress and DNA damage, as it also 
decreases drug accumulation. In the paper II, we demonstrated that IL-6, one of the soluble 
factors secreted by CAFs, attenuates the drug-induced p53 response through STAT3 and 
MDM2. The increased resistance to chemotherapeutic drugs is likely to be a result of the 
combined effect of glutathione and cytokines like IL-6. In the paper III, we found that 
inhibition of the efflux pump MRP1 enhances APR-246-induced mutant p53 cancer cell 
death both in vitro and in vivo. This study also highlighted the impact of the cellular redox 
status and glutathione content on cancer cell survival and anti-tumor activity of APR-246.  
In conclusion, pathways or factors that potentially contribute to drug resistance have been the 
focus of this thesis. Manipulation of these targets in combination with traditional therapies 
may lead to a more efficient cancer therapy. This thesis also highlights CAFs as a potential 
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Cancer is a major public health problem, as well as a complex and dynamic disease. It is also 
a common disease, as in 2018 there were about 18 million new cases of cancer reported and 
9.6 million deaths worldwide 1. In fact, cancer is not just one disease but rather a collection of 
more than 100 different types, with varied characteristics, involving various causes and risk 
factors, and requiring wide-ranging treatments.  
1.1.1 What is cancer and what are its causes? 
Cancer starts when cells in our body grow out of control and crowd out normal cells (Figure 
1). This can happen at any place in the body and cause damage to organs affected. 
Continuation of uncontrolled growth of cells results in rapid cell accumulation that with time 
gives rise to tumor lumps or solid tumors. However, not all lumps are cancer. Unlike 
cancerous or malignant tumors, a benign tumor grows locally without spreading to other parts 
of the body and can be left untreated. A malignant tumor, on the other hand, has the potential 
to invade nearby tissue and later metastasize, i.e. dissociate and spread, to distant areas of the 
body through the blood or the lymphatic system. Meanwhile, there are also cancers that don’t 
form lumps, for example leukemia. 
Cells become cancer cells largely because of errors or mutations in the cells’ DNA – their 
genetic “blueprint”. Mistakes and gene mutations may happen all the time as cells divide, but 
cells are programmed to detect the alterations and repair them. In more severe cases, where 
damages cannot be repaired, the cells will be signaled for programmed cell death. Only cells 
with mutations that manage to escape and survive may give rise to cancer, particularly if the 
mutation affects a gene that regulates cell growth and division. Regardless, it takes more than 
one mutation in a cell for cancer to occur, and because the numbers of gene mutations 
increase and build up over time, the risk of getting cancer is higher as we get older. 
Some of the abnormal changes in cells’ DNA may be passed from generation to generation, 
when an inherited gene mutation is present in the egg or sperm, while other mutations may be 
caused by environmental factors. Acquired mutations are thought to cause a majority of all 
cancer cases, and only about 5-10% are the result of inherited gene mutations 2. 
The risk of developing certain kinds of cancers can be increased by lifestyle or specific 
exposures. Cancer-causing, or carcinogenic, substances have been listed by The International 
Agency for Research on Cancer (IARC) 3, for different groups depending on the potential of 
these chemicals in causing cancer.  
1.1.2 Oncogenes and tumor suppressor genes  
Two main types of genes that play a key role in cancer induction are tumor suppressor genes 
and oncogenes.  
Tumor suppressor genes prevent a cell from undergoing uncontrolled division and abnormal 
growth. They function to halt the cell cycle if there is a problem until certain events are 
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completed. They also induce the necessary DNA repair processes or cell death upon cellular 
damage or mistakes. Tumor suppressor genes including TP53, PTEN (involved in 
counteracting the action of the oncogenes PI3K and Akt) and Rb (responsible for the G1 
checkpoint and blocking S-phase entry) are frequently lost or inactivated in many cancers 4. 
In addition, suppression of tumor suppressor genes occurs much more frequently than 
activation of oncogenes. TP53 will be further discussed in chapter 1.8 THE TUMOR 
SUPPRESSOR p53. 
Proto-oncogenes, which normally regulate cell growth and division, are transformed to 
oncogenes by mutations and become permanently activated. As a result, cells grow and 
divide rapidly through growth-promoting signals. Oncogenes are generally activated by point 
mutation, chromosomal rearrangement, which allows one gene to activate another, or by gene 
duplication and amplification. Most frequently encountered oncogenes in cancers are for 
instance Ras and Myc gene family, and growth factor receptors 4.  
1.1.3 Cancer types 
Cancer can be divided into four major subtypes according to the type of cells that form them5. 
These major classifications are: 
I. Carcinomas 
II. Sarcomas 
III. Hematopoietic malignancies 
IV. Neuroectodermal malignancies 
All cell types in the body can give rise to cancer but the majority of human tumors are 
carcinomas, which arise from epithelial tissues (Figure 1). Epithelial cells are those that line 
the walls of cavities of internal organs, the outer surfaces of organs or cover the surface of the 
body, i.e. the skin. Carcinomas in turn fall into two major categories, which are squamous 
cell carcinomas and adenocarcinomas. Squamous cell carcinomas are generated from 
epithelial cells that form protective cell layers, while epithelial cells that secrete substances 
into the ducts or cavities give rise to adenocarcinomas.  
 
Figure 1. A normal tissue with epithelial cells grown in an orderly way vs. carcinoma with 
tumor cells dividing rapidly 
(Figure adapted from https://www.cancerresearchuk.org/about-cancer/what-is-cancer) 
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The four most common cancers occurring worldwide are lung, breast, colorectal and prostate 
cancer 6, while lung, colorectal, stomach and liver cancer 7 are the most common causes of 
cancer death. In Sweden, skin cancer is also one of the most common cancers 8. 
The rest of malignant tumors are derived from nonepithelial tissues. Various cells of 
connective tissues, such as fibroblasts, adipocytes (fat cells), osteoblasts (bone-forming cells), 
myocytes (muscle cells) and endothelial cells (lining of blood vessels and lymph vessels) can 
give rise to sarcoma. 
Hematopoietic malignancies are caused by different cells that constitute the blood-forming 
tissues, including the bone marrow and the lymphatic system. Leukemia (cancer of white 
blood cells) and lymphomas are examples of this type of cancer. 
Neuroectodermal malignancies are derived from various cells of the nervous system. 
Glioblastomas (develop from star-shaped glial cells), retinoblastomas (develop from the 
immature cells of a retina) and neuroblastomas (develop from immature nerve cells) can be 
included in this group. 
Some types of tumors, such as melanomas that are derived from melanocytes (melanin-
producing cells), do not fit into any of these four groups.  
 
1.2 HALLMARKS OF CANCER 
As previously described, mutations in the DNA are the underlying cause of normal cells 
becoming cancerous. These genetic alterations cause disruption in regulatory circuits that 
control normal cell function and homeostasis, leading cells to turn on genes that are normally 
turned off or silence genes that should be turned on. Even so, development of cancers is a 
multistep process with some common features. Hanahan and Weinberg 9 have summarized 
six distinctive biological capabilities that cells acquire during transformation to malignancy: 
Sustaining proliferative signaling – Cancer cells are self-sufficient in growth signals and do 
not need stimulation from external signals to multiply. They can do so in a number of ways. 
They may, for instance, produce growth factor ligands themselves or increase the levels of 
receptors at the cell surface.  
Evading growth suppressors – Cancer cells are also insensitive to anti-growth signals. 
They, for instance, inactivate tumor suppressor genes or disrupt the growth suppression 
pathway. 
Resisting cell death – Cancer cells learn how to avoid and escape the process of 
programmed cell death apoptosis, by downregulating expression of proapoptotic regulators or 
increasing antiapoptotic or survival factors. 
Enabling replicative immortality – Cancer cells are capable of multiplying without any 
limit, i.e. they are immortalized, by turning on telomerase. 
 
4 
Inducing angiogenesis  – Tumors form new blood vessels from existing ones in order to 
provide themselves with sufficient supply of nutrients and oxygen, as well to remove 
metabolic wastes and carbon dioxide.  
Activating invasion and metastasis – Cancer cells move out of the primary tumor mass, 
invade surrounding tissues and travel to distant sites, where they may found new tumor 
colonies. 
The acquisition of these hallmark capabilities is made possible by genomic instability in 
cancer cells that generates random mutations, and tumor-promoting inflammation 10. 
Cancer has been considered as an inflammation that never really resolves. Persistent 
inflammatory response contributes to hallmark capabilities by supplying bioactive molecules 
to the tumor microenvironment. 
Later, two more capabilities are added as emerging hallmarks 10: 
Reprogramming of energy metabolism – Cancer cells alter the metabolic pathways to 
satisfy their increased needs for energy and building materials.  
Evading immune destruction – Tumor cells develop strategies to bypass the surveillance of 
the immune system, which plays a major role in eliminating them. 
In addition to cancer cells, a repertoire of recruited non-transformed cells also contributes to 
the development of certain hallmark capabilities. These recruited non-transformed cells form 
a permissive microenvironment, called the 'tumor microenvironment', which turns out to be 
crucial for the progression and maintenance of the cancerous cells they surround via a tight 
and dynamic interaction between the two. 
 
1.3 THE TUMOR MICROENVIRONMENT  
Aside from tumor cells, the tumor microenvironment is comprised of cancer stem cells, blood 
vessels including endothelial cells and pericytes, immune inflammatory cells and other 
stromal cells (connective tissue cells) such as fibroblasts (Figure 2). Unlike cancer and cancer 
stem cells, stromal cells in the tumorigenic microenvironment are genetically stable. 
However, they are recruited and reeducated by cancer cells in order to support cancer cells in 
various ways, and may carry epigenetic changes. Hence, they display altered gene 










Figure 2. Tumor cells and the tumor microenvironment 
 
1.3.1 Cancer stem cells 
Cancer cells within a tumor have, in recent years, been considered as heterogeneous cell 
populations. This could in part be a result of the hyperproliferation combined with enhanced 
genetic instability that leads to diverse clonal subpopulations. A solid tumor displays a great 
degree of heterogeneity of tumor cells with various states of differentiation, proliferation 
rates, migratory and invasive capacity, or other features 11,12. More and more evidence points 
towards the existence of cancer stem cells or that a fraction of cells within most tumors has 
acquired properties of stem cells. With self-renewal ability, similar to that of normal tissue 
stem cells, cancer stem cells are able to maintain tumor growth or seed new tumors. They are 




1.3.2 Endothelial cells 
A layer of endothelial cells forms the inner lining of blood vessels. Activation of normal 
endothelial cells by cancer cells causes them to transform into tumor-associated endothelial 
cells with ability to construct new blood vessels by angiogenesis. The balance between pro- 
and anti-angiogenic factors that regulates vascularization in normal tissues is disrupted. 
Instead, the pro-angiogenic stimuli are taking over in this angiogenic switch. One of the 
prominent key regulators for blood vessel sprouting is vascular endothelial growth factor 
(VEGF), which is highly expressed in most tumors. The newly formed vasculature serves as a 
supply line for nutrients, oxygen and other solutes from the bloodstream to cancer cells. It is 
also used for removing waste products 14. 
The tumor blood vessels also differ from their normal counterpart, as they tend to be leaky, 
fragile and highly irregular. Blood flow also tends to be low and abnormal. High proliferating 
cancer cell density around the tumor vessels gives rise to compression of the blood vessels 
and increased microvascular pressure 14. This high microvascular pressure, together with poor 
tumor vessel quality, low blood flow, poor perfusion (blood gets to a tissue) and inadequate 
lymphatic drainage of excess fluid leads to an elevated interstitial fluid pressure in solid 
tumors 15. This results in reduced fluid movement through the interstitium (fluid filled space 
between cells), and becomes an obstacle in cancer therapy. 
1.3.3 Pericytes 
Pericytes are vascular smooth muscle cells or mural cells that wrap around the endothelial 
cells at the surface of the blood vessels. Both pericytes and endothelial cells collaborate with 
each other to structure the vascular basement membrane, in order for vessel walls to 
withstand the pressure of blood flow. They communicate by direct cell-cell contact or 
through paracrine signaling pathways, which allows the exchange of small molecules. Unlike 
normal pericytes, the tumor pericytes appear to be loosely attached to the vasculature and 
exhibit abnormal pericyte behavior or expression profile. In some tumors, a larger number of 
pericytes express alpha-smooth muscle actin (α-SMA), which is normally expressed by cells 
of the smooth-muscle lineages 16,17. 
The recruitment of pericytes into tumors is largely dependent on the platelet-derived growth 
factor (PDGF) signaling, where tumor pericytes express PDGF receptor-β and PDGF-β 
ligand is produced by endothelial cells. By perturbing the expression of PDGFR-β or its 
ligand results in reduced pericyte coverage of tumor vessels, which in turn leads to more 
disordered and defective vasculature 16,17. In consequence, tumor vessels without pericytes 
appear to be more vulnerable and may be a good target for anti-angiogenic therapy.  
Tumor pericytes, despite having structural and behavioral abnormalities, still contribute to 
tumor angiogenesis, provide functions necessary for vessel maintenance and support 
endothelial cell survival. 
1.3.4 Immune inflammatory cells 
In normal wound healing and defenses against inflammation or infection, immune cells 
appear transiently and disappear when the target intruder is destroyed. Tumors, however, 
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have been associated with chronic inflammation or portrayed as wounds that never heal. 
Diverse types of cells of the immune system are, therefore, found to infiltrate tumor tissues. 
Surprisingly, many of these tumor-infiltrating inflammatory cells, including macrophages, 
mast cells, neutrophils, T and B lymphocytes have tumor-promoting effects rather than 
serving as effectors of tumor-antagonizing actions. These cells have been shown to stimulate 
cancer cell proliferation, induce tumor angiogenesis, and support metastasis and tissue 
invasion. Several signaling molecules released by the immune inflammatory cells are also 
linked to their tumor-promoting actions. These include epidermal growth factor (EGF), 
VEGF, fibroblast growth factor 2 (FGF2) and other inflammatory associated chemokines and 
cytokines 10. 
In addition to fully differentiated immune cells, partially differentiated myeloid progenitor 
cells can also be found in tumors. These recruited progenitor cells have been shown to 
support tumor progression and allow cancer cells to evade immune destruction, for instance 
by suppressing cytotoxic T lymphocyte and NK cell activity 10. 
1.3.5 Fibroblasts 
Fibroblasts are spindle-shaped cells and are the most common cell types of connective tissue. 
They produce collagen and components that make up the extracellular matrix (ECM) (Figure 
2), while also supporting the structure of tissues and organs. Fibroblasts also play a critical 
role in wound healing, e.g. when tissues are injured, they are activated and start expressing α-
SMA as well as generate contraction to facilitate wound closure. Once the healing process is 
completed, these activated fibroblasts are removed by apoptosis 18.  
As previously mentioned, tumors have been described as wounds that never heal. Normal 
fibroblasts can be reprogrammed and turn into cancer-associated fibroblasts (CAFs) by a 
variety of chemical signals from cancer cells and remain constitutively active. However, their 
biological roles and properties differ markedly from that of normal fibroblasts.  
CAFs will be discussed in more detail in chapter 1.4.  
 
1.4 CANCER-ASSOCIATED FIBROBLASTS 
Most solid tumors contain activated or cancer-associated fibroblasts (CAFs) and their 
abundance varies between different cancer types. Prostate and breast cancer for instance are 
known to contain high numbers of CAFs. CAFs are also the most abundant cell type in the 
tumor stroma 19. 
1.4.1 Phenotypes and tumor promoting effects of CAFs 
In contrast to normal fibroblasts, CAFs can be characterized with phenotypes such as more 
rapid proliferation rate, enhanced collagen production and secretion of growth factors. They 
are either found to reside at the edge of tumors or disperse through out the tumor mass 20. 
Apart from these phenotypes, they are also a potent supporter of carcinogenesis. They have 
the capability to promote the initiation of epithelial tumor formation, tumor growth and 
progression, angiogenesis, metastasis, inflammation as well as immunosuppression 20-22. 
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CAFs can support tumorigenesis by regulating immune cells and contributing to immune 
escape of tumors 22. Another feature of CAFs is the ability to remodel the ECM. The changes 
in the composition of the ECM influence the stiffness of the tissue, where the tumor ECM is 
denser and stiffer than normal tissue. This has an effect on tumorigenic behaviors and on how 
tumors respond to therapy. The dense and rigid ECM, due to increased production of collagen 
and other ECM molecules by CAFs, can shield cancer cells from therapeutic agents. CAFs 
contribute not only to the ECM modification but also regulate ECM degradation, which then 
facilitates tumor growth, invasion and migration 19,21. 
CAFs also display altered gene expressions compared to their non-tumoral counterpart. Many 
of these genes encode receptors or secreted proteins, which are cytokines, growth factors and 
signaling molecules 23. Several of these proteins are well known for their involvement in 
tumor-stroma cell interaction. CAF-derived chemokine such as stromal-cell-derived factor 1 
(SDF1), also known as CXCL12, enhance cancer cell proliferation and induce angiogenesis. 
This chemokine has also been reported to augment the proliferation, migration, and invasion 
in breast cancer. Overexpression of CAF-derived growth factors, such as transforming 
growth factor beta (TGF-β) and hepatocyte growth factor (HGF), have been shown to 
influence the tumor growth and progression 20,23,24. By expressing members of the matrix 
metalloproteinase (MMP) family, CAFs regulate the degradation of the ECM 19. 
Furthermore, CAFs have also been shown to affect sensitivity of tumor cells to chemotherapy 
and mediate drug resistance, for instance through HGF secretion 20. CAF-mediated resistance 
will be further discussed in section 1.10 CANCER DRUG RESISTANCE. 
1.4.2 Origin of CAFs 
Numerous reports suggest that CAFs can be derived from multiple origins (Figure 3), making 
up a heterogeneous population of cells. Some of them are local fibroblasts, altered after 
continuous exposure to cancer cells. Mesenchymal stem cells (multipotent stromal cells) in 
the vicinity of tumors can differentiate into CAFs. Another possible source of CAFs is 
recruited smooth muscle cells, which generally express high levels of α-SMA. Cells of 
epithelial origin also contribute to the CAF population, as they undergo an epithelial-to-
mesenchymal transition (EMT). These cells exhibit fibroblast morphology and express at the 
same time keratin that is only present in epithelial cells. Other studies have demonstrated that 
endothelial cells can give rise to CAF-like cells, by undergoing endothelial-mesenchymal 
transition (EndMT) 19,20,24. These cells often express VEGF. In addition, growth factors, such 
as TGF-β and PDGF, have been shown to be key mediators in activating and regulating 
CAFs 25. 
In the past few years, a series of studies has demonstrated that different subtypes of CAFs, 
most likely with different cell-of-origin, differ in functions, confirming the existence of 
functional heterogeneity among CAFs 25-30. The breadth of CAF functions, as well as 







Figure 3. Origin of CAFs 
 
1.4.3 Common CAF markers 
The heterogeneity found within the fibroblasts, combined with the presence of multiple 
subpopulations, make it difficult to identify CAFs based on expression of specific markers. 
However, they are frequently described to be upregulated in α-SMA, vimentin (a marker of 
mesenchymal cells), fibroblast-specific protein 1 (FSP1), fibroblast-activated protein (FAP) 
and PDGFR-β, while caveolin-1 (a protein of caveolae, lipid raft) and laminin (largely 
expressed in epithelial basement membranes) are reported to be downregulated in CAFs 19-
21,24. These markers still do not mark all or are unique to CAFs. 
 
1.5 SECRETED FACTORS AND CYTOKINES IN CANCER 
As mentioned earlier, cancer cells use different tactics to promote their own growth and 
survival. In order to do so, they communicate with each other and with its healthy neighbor 
cells through signaling pathways mediated by secreted low-molecular-weight factors and 
signaling molecules. These secreted factors and signaling molecules, also called cytokines, 
play an important role in this communication, and they are rapidly synthesized by the 
producer cells. These producer cells are often adjacent to target cells, which facilitates the 
binding of the signaling molecules to specific surface receptors on the target cells. Cancer 
cells, for instance, interact with nearby cells in a paracrine manner by releasing the secretory 
factors and cytokines into the tumor microenvironment, which consequently stimulates non-
cancerous proximal cells to produce signaling molecules as a response. This complex 
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network of interaction between tumor cells and their microenvironment results in dynamic 
feedback loops of stimuli responses. However, this interaction is not only limited to target 
cells in the neighborhood, as some signaling molecules can bind to distant target cells, acting 
in an endocrine fashion. Tumor cells also secrete soluble factors and cytokines to influence 
themselves and exert their actions in an autocrine manner.  
The tumor microenvironment often serves as a reservoir of growth factors and cytokines, 
each of which may affect cancer cells in several ways. The signaling molecules can directly 
stimulate the proliferation, angiogenesis, and migration, and reduce drug sensitivity of the 
tumor cells. They can indirectly affect the tumor microenvironment and also alter the 
production of other cytokines to the benefit of cancer cells. Hence, this bidirectional crosstalk 
between cancer cells and its useful neighbor through signaling molecules assure both 
development and maintenance of the tumor itself and of tumor-supportive properties of the 
microenvironment.  
CAFs secrete a variety of soluble factors with protumorigenic activities. Some of the known 
secreted factors are further summarized in Table 1 19,20,24,31,32:  
 
Table 1. A list of secreted factors derived from CAFs and their potential effects on malignant 
cells 
CAF-derived factors Effects on malignant cells 
C-C motif chemokine ligand 5 (CCL5) ñ Metastasis 
Connective tissue growth factor (CTGF) ñ Angiogenesis 
ñ Invasion 




Epidermal growth factor (EGF) ñ Proliferation 
Fibroblast growth factor (FGF) ñ Angiogenesis 










Matrix metalloproteinase MMP-1, MMP-2  
and other members of the MMP family  
(through ECM remodeling) 
ñ Proliferation 
ñ Migration/invasion/metastasis 
Matrix metalloproteinase MMP-13  
(through ECM remodeling) 
ñ Angiogenesis 
Stromal cell-derived factor 1 (SDF1) or CXCL12 ñ Proliferation 
ñ Angiogenesis 
ñ Migration/invasion/metastasis 




Vascular endothelial growth factor (VEGF) ñ Angiogenesis 
Wnt2 and other members of the Wnt family ñ Proliferation 
ñ Invasion 
 
IL-6 will be discussed in detail in the next chapter. 
 
1.6 INTERLEUKIN-6 
Interleukins were initially thought to be expressed exclusively by leukocytes but were later 
found to be produced by other cells as well. Interleukin-6 (IL-6), produced for instance by 
monocytes, macrophages, T cells, mast cells, keratinocytes, fibroblasts and endothelial cells, 
is a cytokine with a molecular mass of 21-28 kDa 33,34. It is involved in the host response to 
injury or infection, immune response and inflammation, and it signals through the 
gp130/JAK/STAT pathway. 
1.6.1 IL-6 biological functions 
IL-6, a pleiotropic (multifunctional) cytokine, plays an essential role in host defense as it has 
wide range of immune and hematopoietic activities, and it regulates the acute-phase response 
triggered by infections or injuries. IL-6 is an important inducer of the acute phase response in 
the liver and it also contributes to the body’s defense by inducing fever 33. In addition to its 
role in the acute phase response, it has the ability to induce differentiation of B cells 35, and 
proliferation and activation of T cells. Evidence has also shown that IL-6 is capable of 




The IL-6 levels in the blood under normal circumstances are around 1-2 pg/ml 36, but can be 
elevated in patients with infectious diseases and inflammation 37,38. 
1.6.2 IL-6 signaling 
Classical IL-6 signaling requires IL-6 binding to its non-signaling α-receptor subunit, IL-6R, 
on the plasma membrane. This ligand binding leads to recruitment of the signal-transducing 
receptor subunit gp130 to the receptor complex. This then induces gp130 homodimerization, 
which leads to the activation of Janus kinases (JAKs) and transcription factor of the STAT 
family 34 (Figure 4). While expression of IL-6R is limited to hepatocytes and subsets of 
leukocytes 39, gp130 is found in almost all organs 40. IL-6 can also trigger signal transduction 
via extracellular secretory soluble receptor (sIL-6R), which forms a complex with gp130 
expressed by any cell. The receptor subunit gp130 is also shared by the receptors of other IL-
6 family of cytokines, including IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM) 
and ciliary neurotrophic factor (CNTF) 34.  
The Janus kinases JAK1, JAK2 and TYK2 become activated after the assembly of receptor 
complexes, and subsequently phosphorylate gp130 at specific tyrosine residues within the 
cytoplasmic part. These phosphotyrosine residues create docking sites for STAT factors 
STAT1 and STAT3, which in turn become phosphorylated and activated. Recruitment and 
phosphorylation of STATs at specific tyrosine residues (STAT1: tyrosine 701 and STAT3: 
tyrosine 705) stimulates them to form dimers, translocate into the nucleus, and bind to 
enhancer elements of target genes. Consequently, this leads to transcriptional activation of the 
target genes 34 (Figure 4).  
IL-6 may also activate mitogen-activated protein kinase (MAPK) via JAK, which results in 
enhanced cell growth, proliferation and mitosis. Another signaling pathway that is induced by 
IL-6 and JAK activation is the phosphatidylinositol 3-kinase/Akt kinase (PI3K/Akt) pathway. 
JAK-dependent PI3K activity leads to anti-apoptosis signaling and increased cell survival 41. 
1.6.3 Role of IL-6 in cancer 
IL-6, one of the major cytokines in the tumor microenvironment, and is often found in high 
concentrations as a result of overproduction by not only non-cancerous cells of the tumor 
microenvironment but by malignant cells as well. In cancer, IL-6 acts as a pro-inflammatory 
cytokine and supports tumorigenesis. Both autocrine secretion of IL-6 by cancer cells and 
paracrine secretion by the tumor microenvironment are known to contribute to tumor 
proliferation, metastasis, angiogenesis and therapeutic resistance in many cancers. In the case 
of prostate cancer, inhibition of IL-6 increases the sensitivity of prostate tumor cells to anti-
cancer therapies, and high serum IL-6 levels have been reported to correlate with poor 
therapeutic response 42. 
Elevated IL-6 levels are often detected in affected tissues or serum from patients diagnosed 
with cancer. As high as 6-12 pg/ml of IL-6 has been measured in the serum from prostate 
cancer patients 43-45. Moreover, IL-6 levels have been reported to be higher in prostate cancer 
patients with metastatic disease (bone or lymph node metastases) than in patients with earlier 




Figure 4. IL-6 signaling through the gp130/JAK/STAT3 pathway 
P = Phosphorylation 
 
with castration-resistant prostate cancer also had elevated levels of IL-6 compared to the 
hormone sensitive group 41.  
Prostate cancer cells are normally dependent on androgens, especially testosterone. Patients 
with advanced disease are submitted to hormonal castration, also called androgen suppression 
therapy. However, the androgen receptor can be activated by other cytokines and growth 
factors, including IL-6, in the absence of androgen. Castration-resistant prostate cancer has 
therefore been observed after hormonal castration, when the tumor shows decreased 
sensitivity to the treatment with androgen deprivation. This is a problem as it is an incurable 
stage of the disease. Eventually patients develop metastases and most patients die from 
recurrent castration-resistant prostate cancer 41.  
Increased serum levels of IL-6 have also been associated with an adverse prognosis in 
patients with different types of cancer, including prostate cancer 46. Shorter survival in 
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prostate cancer patients has been shown to correlate with increased IL-6 levels and aggressive 
disease 41. 
Furthermore, STAT3 activation mediated by IL-6 can regulate the process of apoptosis. 
STAT3-dependent upregulation of anti-apoptotic regulators, such as Bcl-2, Mcl-1, Bcl-xL 
and survivin, helps cancer cells to resist cell death. The Bcl-2 proteins Bcl-2 and Mcl-1 
interact for instance with Bax and prevent the induction of apoptosis 47. 
 
1.7 GLUTATHIONE 
Glutathione is a tripeptide of the amino acids glutamic acid-cysteine-glycine (Figure 5) with a 
molecular weight of approximately 307 Da 48. Stromal cells are able to secrete glutathione 
and the amino acid cysteine, to neighboring cancer cells and promote cancer cell survival 
49,50.  
Glutathione plays a central role in the detoxification of xenobiotics (exogenous and foreign 
substances for the body) and endogenously generated reactive metabolites. It is the major 
antioxidant produced by the cells and it protects our body from free radicals, which are highly 
reactive forms of oxygen or nitrogen with unpaired electrons and readily react with other 
molecules, causing damage to cells and its DNA. By directly binding to harmful oxidative 
molecules, glutathione neutralizes a wide range of oxidants. Glutathione is also used as a 
cofactor by several antioxidant enzymes 51. 
1.7.1 Glutathione biosynthesis 
Glutathione synthesis involves two enzymatic steps, which includes glutamate cysteine ligase 
(GCL) in the first step and glutathione synthetase (GSS) in the second (Figure 5). The rate of 
glutathione synthesis is mostly determined at the first step by two factors: cysteine 
availability and GCL activity 52. Cysteine is normally derived from protein breakdown or by 
conversion of methionine through the transsulfuration pathway 48,52. Furthermore, both 
cysteine and its oxidized form cystine can be imported via different membrane transporters. 
Cystine that occurs mainly in a more oxidative environment is imported by the 
cystine/glutamate antiporter xCT (SLC7A11). The imported cystine is rapidly reduced to 
cysteine by the thioredoxin (Trx) system or the glutathione system 48,53 (Figure 5). 
Glutathione exists in cellular systems in two states. The free glutathione, which is the reduced 
form (GSH), makes up the vast majority in the intracellular compartment and is present at 
millimolar concentrations under normal conditions. Meanwhile, oxidized glutathione (GSSG) 
is estimated to constitute less than 1% of the total glutathione. 90% of glutathione can be 





















Figure 5. The synthesis of glutathione from its constituent amino acids involving two enzymatic 
steps 
1.7.2 Glutathione functions 
Oxidants or reactive oxygen species (ROS) are generated by aerobic cells as products of a 
normal cellular metabolism and most of them by the mitochondrial respiratory chain. During 
endogenous metabolic reactions, the reactive metabolites, such as hydrogen peroxide (H2O2), 
hydroxyl radical (OH) and superoxide anion (O2-), are produced. Under conditions of cell 
injury or stress, ROS production is further increased, resulting in an imbalance in cellular 
redox homeostasis, which can cause severe damage to the cell. To prevent irreversible cell 
damage, an increase of ROS leads to induction of the cellular protective mechanisms referred 
to as antioxidant defenses. Antioxidants are induced to protect the cells and their components, 
including mitochondria and DNA, against the increased levels of oxidant species. Cells have 
non-enzymatic and enzymatic ways of ROS elimination. Detoxification from ROS can be 
facilitated by glutathione, a low-molecular weight thiol, or by enzymatic antioxidants such as 
glutathione reductase (GR), glutathione peroxidase (GPX), peroxiredoxin (PRDX), catalase, 
and superoxide dismutase (SOD). These antioxidants aim to control the balance between 
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production and removal of ROS, and thereby restore the redox homeostasis 54,55. Among the 
antioxidants involved in the maintenance of the intracellular redox balance, an essential role 
is played by glutathione. Depletion of glutathione due to excessive antioxidant protection or 
detoxification may create an imbalance in redox homeostasis. Reactive metabolites, such as 
H2O2, can be metabolized by GPX, and this reaction involves oxidation of GSH to GSSG. In 
order to limit oxidative damage, GSSG is reduced back to GSH by GR (Figure 6) at the 
expense of NADPH 52.  
Other harmful and toxic substances can be processed by forming conjugates with glutathione. 
The conjugation occurs either spontaneously or is catalyzed by glutathione-S-transferase 
(GST) 52. GST attaches glutathione to the toxins and makes them more water-soluble and 
ready to be eliminated. Furthermore, glutathione regulates thiolation of proteins, which is a 
common feature of redox signal transduction and is essential for several biological processes, 
such as glycolysis, proteolysis, modulation of enzymes, and regulation of protein function 56. 
At the same time, glutathione also serves as a source of cysteine. Glutathione levels are also 
maintained through a salvage pathway, the γ-glutamyl cycle, which involves the release of 
glutathione from the cell, the breakdown of glutathione, and the transportation of its amino 
acids back into the cell. γ-glutamyl transpeptidase (GGT) is a membrane bound enzyme 
involved in the transfer of glutamyl moiety, which results from the GSH breakdown, and 
hence allows the γ-glutamyl cycle to take place 52 (Figure 6). 
 
Figure 6. The γ-glutamyl cycle 
aa = amino acids 
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1.7.3 Role of glutathione in cancer 
Oxidative stress, an imbalance between production and disposal of free radicals and ROS, is a 
common feature of different types of cancer. Prolonged exposure of high levels of ROS, due 
to sustained stress, leads to perturbations of redox balance and oxidative stress. This 
potentially contributes to increased DNA damage or mutations and genome instability, and 
triggers neoplastic transformations. Enhanced ROS or oxidative stress can also stimulate 
cellular proliferation by inducing regulators of cell growth, proliferation and cell cycle 
control or by activating certain signaling pathways that contribute to tumor development. 
Cancer cells exhibit higher levels of basal ROS than normal cells, and increased ROS or 
oxidative stress plays a great role in initiation and progression of many cancers, including 
prostate cancer 54.  
To survive in the presence of excessive oxidative stress, tumor cells counteract ROS by 
relying on glutathione or strategically adjusting several antioxidant enzymes. Accordingly, 
elevated glutathione levels can be observed in various types of tumors, and are correlated 
with increased proliferation and metastatic activities of malignant cells. Furthermore, the high 
glutathione content in tumor cells are often associated with higher levels of glutathione-
related enzymes or glutathione-transporting export pumps. The expressions and activities of 
glutamate cysteine ligase (GCL), the key enzyme of glutathione biosynthesis, are frequently 
enhanced. Elevated levels and activity of γ-glutamyl transpeptidase (GGT), the essential 
enzyme in the γ-glutamyl cycle, have also been observed in several cancers, and are 
correlated with increased invasive growth 52.  
Chemotherapeutic drugs, such as doxorubicin and taxol, generate high levels of ROS and 
oxidative stress57,58. As a consequence, tumor cells make use of accessible supply of 
glutathione or its precursor amino acids to inhibit drug-induced ROS and oxidative stress. In 
addition to interaction with ROS, glutathione also contributes to drug resistance by directly 
binding to or reacting with drugs. High glutathione levels in combination with elevated 
expression of glutathione-S-transferase (GST) can increase conjugation and detoxification of 
chemotherapeutic agents. As a consequence, tumor cells become more resistant to 
chemotherapy. Moreover, cells that overexpress GGT have been demonstrated to be more 
resistant to anti-cancer agents such as doxorubicin, cisplatin and 5-fluorouracil (5-FU) 52.  
Hence, the regulation of ROS or oxidative stress has an impact on both tumor development 
and responses to chemotherapy. 
 
1.8 THE TUMOR SUPPRESSOR TP53 
A key player in the protection against cancer as well as in regulating responses to 
chemotherapeutic drugs, is the tumor suppressor gene TP53. This gene codes for the p53 
protein that acts as “the guardian of the genome”. It plays an essential role in protecting us 
from cancer by sensing cellular stress, working to repair the damage, or triggering cell death 
through apoptosis.  
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1.8.1 p53 function and its targets 
The p53 protein is widely known for its role as a DNA-binding transcription factor that 
activates the expression of stress response genes. Once cells sense DNA damage or other 
cellular insult, sensor proteins alert p53, which then leads to induction of p53’s target genes 
that are responsible for executing the p53 response. As a result, cells undergo p53-dependent 
cell cycle arrest, DNA repair, or cell death (Figure 7). In that manner, p53 functions as an 
emergency brake to prevent transformation and proliferation of cells that carry damaged 
DNA or genetic lesions that lead to dysregulated growth. It may also act as a major barrier to 
tumor progression by preventing the accumulation of oncogenic mutations 59. 
Among the most well-known p53 targets, the cell cycle inhibitor p21, also known as WAF1 
or cyclin-dependent kinase inhibitor 1 (CDKN1A), was the first to be identified 60. p21 is 
transcriptionally induced by p53 to regulate cell cycle progression, which predominantly 
leads to cell cycle arrest 61. However, p21 can also be activated via p53-independent 
pathways 62. Some other p53 target genes play key roles in the induction of apoptosis as a 
response to cellular stress. Upregulation of pro-apoptotic genes such as Bax, PUMA, and 
Noxa triggers cell death 63 (Figure 7). 
Another important target of p53 is Mdm2, which is a negative regulator of p53 itself (Figure 
7). Expression of the Mdm2 gene is regulated by p53 and is at the same time the key 
regulator of p53 protein stability. The MDM2 protein binds to p53 and targets it for ubiquitin-
mediated proteolysis. p53 activation, for instance through phosphorylation at serine 15 
following DNA damage, disrupts binding to MDM2. As a consequence, the p53 protein is 
stabilized. In this way, the interaction between p53 and MDM2 creates a negative feedback 
loop 61. 
In addition to its critical role in DNA damage response, growth arrest and apoptosis, p53 has 
also been identified as an important regulator of other cellular processes, such as senescence, 
autophagy and metabolic pathways, including modulation of glucose uptake, dampening 
glycolysis and enhancement of mitochondrial respiration 64. p53 also has the ability to 
regulate redox homeostasis. p53-dependent induction of p21 protects cells against oxidants 
by inducing the antioxidant regulator Nrf2, while targets such as Bax, PUMA and Noxa are 
prooxidant and promote apoptosis. p53 also has other target genes that are involved in redox 
regulation 65. 
Furthermore, p53 is critical for the cellular response to chemotherapeutic drugs. Several 
chemotherapeutic agents induce DNA damage and hence cause cytotoxic effects on actively 
proliferating cancer cells. The cytotoxic action of these agents leads to execution of the cell 
death program by p53. Therefore, p53 is important for the cellular response to anti-cancer 
agents, and the involvement of p53 in this response suggests a mechanism through which 




Figure 7. The p53 pathway and p53-mediated tumor suppression. 
ATR = Ataxia telangiectasia and Rad3-related protein, ATM = Ataxia telangiectasia mutated 
protein kinase, Chk1 = Checkpoint kinase 1, Chk2 = Checkpoint kinase 2, γ-H2AX = Gamma-H2A 
histone family member X (phosphorylated H2AX) 
1.8.2 TP53 inactivation and mutations 
Given the importance of p53 in cellular stress responses and elimination of incipient tumor 
cells, it is not surprising that p53 is frequently downregulated or inactivated in cancer. During 
cancer development, cells may find many ways to repress p53 without the need to mutate the 
TP53 gene. Mechanisms of p53 inactivation include complex formation with viral proteins 
such as the human papilloma virus (HPV) E6 protein, elevated expression of MDM2, or 
deregulation of upstream signals, resulting in disruption of the p53 signaling pathway. 
Regardless, mutations in the TP53 gene have been found in about half of human cancers 67. In 
some types of cancer, such as ovarian cancer, the frequency is as high as 95% 68, while in 
prostate cancer it is relatively low 69,70. The majority of TP53 alterations are missense 
mutations in the DNA-binding core domain 67, which results in deficient DNA binding and 
hence failure to activate p53 target genes. 
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Inactivation of p53 is a critical step during tumor evolution. Mutations in the TP53 gene 
essentially lead to loss of its tumor suppression functions, allowing cells to escape from 
apoptosis and sustain tumor growth. Besides loss of function of the protein, TP53 mutations 
may also endow the mutant protein with new functions. Many mutant p53 proteins acquire so 
called gain-of-function activities and oncogenic properties that are crucial for tumor 
progression. In most cases, mutant p53-carrying tumor cells accumulate high levels of 
functionally deficient p53 protein 67, unlike normal cells where p53 is expressed at low levels 
due to its short half-life 71 and only accumulates when cells experience certain stress 
conditions. Following recovery from cellular stress, p53 normally returns to a basal level, 
which is maintained by MDM2. Additionally, high levels of mutant p53 protein in tumor 
cells is often linked to increased resistance to anti-cancer treatments and other survival 
advantages 72. Tumors that carry mutant TP53 are generally more resistant to therapy 73. 
1.8.3 Rescuing the tumor suppressor p53 
Since p53 mutation is common in cancer, intense efforts are being made in academia and 
industry to develop drugs that either inhibit the MDM2-p53 interactions, or target mutant p53 
to restore its tumor suppression function 59. However, it is a challenge to design a compound 
that efficiently repairs mutant p53 and restores its multiple functions. Also, mutant p53 is a 
heterogeneous group of proteins that includes both DNA contact and structural mutants, and 
therefore mutant p53 is a difficult therapeutic target. However, our lab has developed a small 
molecule, known as APR-246 (or PRIMA-1Met)74-76 that is currently tested in phase III 
clinical trials in combination with azacitidine (a hypomethylating agent) in myelodysplastic 
syndrome (MDS) (a malignancy where immature blood cells in the bone marrow fail to 
mature). For more information regarding the clinical trials, see clinicaltrials.gov. In an earlier 
phase I/II clinical studies, APR-246 showed a favorable toxicity profile 77. APR-246 is a 
prodrug that is converted to the active compound methylene quinuclidinone (MQ), a Michael 
acceptor that binds covalently to cysteines in p53, stimulating refolding to wild type 
conformation. This “wild-type-like” p53 can induce downstream target genes and trigger cell 
death 74,76,78,79 (Figure 8). Thus, APR-246/MQ restores wild type activity to mutant p53. 
 
 




1.9 CANCER TREATMENT 
In order to plan treatment and predict the patient’s prognosis, cancer staging is used to help 
determine the extent of the disease. Staging is a way to describe the size of the cancer and 
how far it has spread. There are two main types of staging systems, the TNM (Tumor, Node, 
Metastasis) system and the numbered cancer stage system. The TNM system refers to how 
big the initial cancer is, and whether it has spread to the lymph nodes and metastasized to 
other parts of the body. The number system divides cancers into stages, typically labeled 
from I to IV with IV being the most serious and indicating that the cancer has spread to other 
organs 80. 
Given the complexity and multitude of behaviors for various forms of cancer, it is not always 
easy to decide on the most optimal treatment. Some tumors grow and spread fast while others 
are less aggressive. The choice of treatment for each patient depends, again, on the type and 
stage of cancer, as well as where it originated. Other factors such as how the treatment affects 
the patient’s normal body functions or the patient’s age and overall health are also 
considered. 
The traditional therapies and most widely used treatment options are surgery, chemotherapy 
and radiation therapy (Figure 9). Surgery is used to remove solid tumors, while radiation 
works by breaking the cells’ DNA using high-energy electromagnetic waves. Surgery and 
radiation are usually local treatments, aimed at the site of the tumor. Chemotherapy, on the 
other hand, is systemic and exposes the whole body. Furthermore, radiation and 
chemotherapy can be used after the surgery to kill any remaining cancer cells, or used to 
shrink a tumor before surgery.  
Sometimes chemotherapy is the only cancer treatment needed. To date, there are more than 
100 chemotherapeutic agents available. Some cancers can be treated with a single anti-cancer 
agent, but often several are used in a certain order or in certain combinations. Combination 
chemotherapy takes advantage of using drugs that work in diverse ways together to kill 
cancer cells more efficiently. This may help lower the risk of cancer becoming resistant to 
any drug. Chemotherapeutic or anti-cancer agents can be classified by their mechanisms of 
action. Most of them target cells at different phases of the cell cycle. Therefore, 
chemotherapy is most effective at killing cells that are rapidly dividing, like cancer cells.  
Despite the accelerated rate of cell division usually found in cancers, which make them better 
targets for cytotoxic chemotherapy, the drugs do not distinguish between healthy and 
cancerous cells. Therefore, normal cells will be harmed along with the cancer cells. This 
unfortunately results in side effects that in some cases can be severe. For this reason, there is 
always a constant need to develop or improve drugs that can reduce potential side effects 
without compromising the clinical efficacy. 
More recently, novel therapies such as hormone therapy, immunotherapy and targeted 
therapy tailored for a specific type of cancer, have been added to the therapeutic arsenal 
(Figure 9). These are usually adjuvant treatments and often have fewer side effects than 
chemotherapy. For early prostate cancer, common treatment options are surgery, also called 
radical prostatectomy, and radiation therapy. Radical prostatectomy is the removal of entire 
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prostate gland and some of the tissue around it. In cases of metastatic prostate cancer, 
radiation therapy along with hormone therapy, also called androgen suppression therapy, or 
chemotherapy may be used. 
Targeted therapy refers to the use of drugs that attack cancer cells with higher selectivity than 
the traditional chemotherapeutic drugs, by taking advantage of differences between normal 
cells and cancer cells, usually specific gene alterations that drive cancer cell growth. Over the 
last few decades, a number of new drugs have been developed to target proteins that cancer 
cells depend on. A good example is imatinib or Gleevec, a drug that inhibits the oncogenic 
BCR-ABL kinase that is often activated in chronic myeloid leukemia (CML) 81. APR-246 has 
been developed to target and reactivate mutant p53 protein. IL-6 receptor and STAT3 
inhibitors aim to target cancer cells that rely on the IL-6/JAK/STAT3 signaling pathway to 
survive. 
Uncovering genetic lesions in cancer not only provides useful information to guide treatment 



















Figure 9. Cancer treatment options 
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1.10 CANCER DRUG RESISTANCE 
Initially, most tumors respond well to therapy but tend to relapse following treatment. 
Development of drug resistance and relapse therefore remain as important obstacles to 
successful cancer therapy. Cancerous cells are persistent in finding ways to adapt and 
overcome therapy, making the problem very challenging. There are numerous molecular 
mechanisms that enable cancer cells to evolve therapy resistance. 
1.10.1 Interactions with the surrounding microenvironment 
The reappearance of tumor cells after the insult of therapy, even if the number of cells is very 
small, can unfortunately seed the growth of a new tumor. Due to the presence of multiple 
clones in a tumor, small subpopulations of cells may survive treatment and then be further 
selected, resulting eventually in tumor relapse 82. 
Moreover, cancer cells may be shielded by interacting with their microenvironment. The 
tumor microenvironment provides the aid they need and protects them from therapy, which 
may consequently lead to less effective treatment. One mechanism by which the tumor 
microenvironment confers drug resistance is soluble factors. Hepatocyte growth factor 
(HGF), often overexpressed by CAFs, has been shown to play an essential role in the 
development of drug resistance to different kinase and growth factor receptor inhibitors. For 
instance, HGF contributes to resistance to serine/threonine-protein kinase B-Raf 
inhibitor used to treat melanoma, human epidermal growth factor receptor 2 (HER2) inhibitor 
used as a treatment for HER2 positive breast cancer, and epidermal growth factor receptor 
(EGFR) inhibitor for colorectal cancer 83. C-C motif chemokine ligand 2 (CCL2), which can 
be induced by CAFs, has also been reported to confer resistance to paclitaxel (also known as 
taxol) and docetaxel in prostate cancer 83. Another study demonstrated that prostate 
fibroblasts are able to attenuate the effects of chemotherapy through secretion of WNT16B 
and thus promote tumor cell survival 84. 
The interstitial fluid pressure, which is normally regulated through interactions between 
extracellular matrix (ECM) molecules and stromal cells, is abnormal in tumor tissues. Many 
solid tumors show an increased interstitial fluid pressure when compared to their 
surroundings, due to features such as blood and lymph vessel abnormalities, increased 
number of fibroblasts and a dense network of collagen fibers in the ECM 15. Dense and stiff 
ECM, as well as high interstitial fluid pressure caused by CAFs, are two critical barriers for 
cancer therapy. These two factors decrease the amount of drug that reaches the tumor cells 
and thus limit the efficiency of drug penetration, resulting in poor anti-tumor therapy 
response 15,85. 
1.10.2 Alterations within the cancer cells 
Cancer cells are masters of adaptation. In order to elude treatment, they are able to alter drug 
uptake, efflux, and detoxification to limit the intracellular concentration of various 
therapeutic compounds. The drug resistance can result from modification of the activity or 
expression of surface receptors and transporters. For instance, increased expression of the 
ATP binding cassette (ABC) membrane transporters results in enhanced drug efflux. Among 
the known ABC transporters, multidrug resistance 1 (MDR1), multidrug resistance-
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associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) have frequently 
been correlated with cancer chemoresistance 82. 
Cancer cells are also able to circumvent the effects of the drugs by preventing anti-cancer 
drugs from undergoing metabolic activation, or inactivating them through conjugation to 
glutathione. The GSH-conjugated compounds become substrates for ABC transporters, such 
as MRP1, which increases the export of drugs from cells 82. Glutathione can also stimulate 
the activity of MRP1 and further facilitate drug transport 86. In addition, MRP1 plays a role in 
redox regulation and the cellular efflux of GSH and GSSG, influencing the susceptibility of 
cancer cells to oxidative stress 87. 
Furthermore, the use of drugs or inhibitors that target one specific protein alone will likely 
lead to selection for mutations in the target protein that make the drug ineffective after a long-
term treatment. Alternatively, cancer cells discover parallel pathways that support their 
survival, which then leads to amplification of alternative oncogenes and activation of other 
survival pathways 82. 
Because of the flexibility of cancer cells and the ongoing selection for enhanced cell survival 
in a developing tumor, cancer cells can often find ways to evade programmed cell death 
induced by therapy. Apoptotic pathways are frequently disrupted in tumor cells 82. Indeed, 
p53 that plays a critical role in inducing apoptosis in response to treatment is mutated and 
linked to chemoresistance in many cancers 88. For instance, TP53 mutations have been 
correlated with acquired resistance to doxorubicin in patients with advanced breast cancer 89. 
A very recent study showed that a mutant TP53 RNA expression signature correlates with 
reduced survival in eleven cancer types 90. In addition to mutations in TP53 itself, p53 activity 
may indirectly be affected due to dysregulation of factors upstream of p53, e.g. proteins that 
are involved in the DNA damage response 82 (Figure 7). Moreover, p53 function can also be 
disrupted due to alterations of negative p53 regulators such as MDM2, which results in 













2 AIMS OF THE THESIS 
The overall aim of this thesis was to elucidate pathways or mechanisms of CAF-mediated 
drug resistance in cancer, and to investigate alternative targeted therapy. 
The specific aims of the papers were: 
 
Paper I: To investigate the impact of human prostate CAFs on chemotherapy resistance and 
prostate cancer cell survival, as well as the mechanism underlying this effect. 
 
Paper II: To examine the role of CAF-derived soluble factors, particularly IL-6, on drug 
resistance and drug-induced p53 response in prostate cancer cells. 
 
Paper III: To further clarify the mechanism of action of the mutant p53-reactivating 






3 RESULTS AND DISCUSSION 
3.1 PAPER I 
Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-
induced prostate cancer cell death. 
Cells of the tumor microenvironment have in recent years become increasingly recognized as 
critical players in tumor development and progression, as well affecting therapeutic 
outcomes. CAFs are the most abundant cell type in the tumor microenvironment and prostate 
cancer is known to contain high numbers of these cells. Drug resistance in prostate cancer 
also remains a challenge to successful treatment. Therefore, I have investigated the role of 
prostatic CAFs in conferring drug resistance and promoting prostate cancer cell survival. In 
particular, I have examined how CAFs affect the response to different chemotherapeutic 
agents in prostate tumor cells carrying wild type TP53.  
Prostate cancer cells were co-cultured with CAFs and treated with different DNA-damaging 
agents, including doxorubicin, taxol and mitomycin C. In all three cases, I observed an 
increase in tumor cell survival and attenuation of the drug-induced p53 response. Medium 
conditioned by CAFs showed comparable effects on tumor cell death and p53 induction, 
indicating that CAFs modulated the drug sensitivity through one or several soluble factors. 
Cancer cells that were co-cultured with CAF-conditioned medium also demonstrated lower 
levels of DNA damage, drug accumulation and ROS after exposure to doxorubicin, as 
compared to cancer cells grown in fresh medium. In line with this, I observed enhanced 
intracellular levels of glutathione in cancer cells in the presence of CAF-conditioned medium, 
as well as elevated levels of oxidized glutathione in CAF-conditioned medium. Interestingly, 
both glutathione and its precursor cystine were able to decrease doxorubicin content in cancer 
cells, although to a different extent. All of this together argues that CAFs protect cancer cells 
by decreasing sensitivity to anti-tumor agents through glutathione, which modulates the redox 
balance and drug-induced ROS levels in cancer cells, and possibly also interferes with the 
amount of drug that reaches the cancer cells. 
Whether decreased doxorubicin accumulation was a result of reduced drug influx, increased 
efflux or other factors have not been thoroughly investigated in this study. A rescue 
experiment with an MRP1 inhibitor was performed in the attempt of finding out whether the 
MRP1 transporter was involved, given that doxorubicin, taxol and glutathione are substrates 
for this pump. However, there was no difference in the amount of doxorubicin accumulated 
in the tumor cells cultured with CAF-conditioned medium or fresh medium, and no 
conclusions were drawn based on those results.  
In summary, I have identified glutathione secreted by CAFs as a critical component in the 
tumor microenvironment, which has the potency to reduce the chemotherapeutic drug 
response in prostate cancer cells. CAF-derived glutathione is taken up by cancer cells in order 
to shelter them from chemotherapeutic agents, as well as drug-induced damage and stress. 
Consequently, the tumor cells are able to survive the treatment. 
 
28 
From this study, I gained a better understanding of how CAFs mediate protection of cancer 
cells against chemotherapeutic drugs and revealed a possible mechanism underlying this 
effect. The knowledge gained may provide opportunities to improve cancer treatment by 
targeting CAFs or interfering with interaction between stroma and tumor cells. The strategy 
of inhibiting glutathione production by CAFs or blocking uptake and resynthesis of 
glutathione by cancer cells, in combination with other chemotherapeutic drugs, may allow 
more efficient elimination of tumor cells. 
 
3.2 PAPER II 
Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to 
doxorubicin in prostate cancer cells. 
In the process of identifying CAF-derived soluble factors that are responsible for increased 
drug resistance in the previous study, I also used a cytokine array approach and was able to 
detect a number of cytokines and growth factors in the CAF-conditioned medium. Several of 
these soluble factors were secreted only by CAFs and not by cancer cells. The fresh medium 
also did not contain these components. Among the identified secreted factors, I tested our 
hypothesis using recombinant HGF, IL-6 and osteoprotegerin (OPG), a soluble member of 
the tumor necrosis factor (TNF) receptor superfamily. Only IL-6 showed capacity to enhance 
cell survival and reduce the p53 response to doxorubicin in prostate cancer cells, without 
affecting drug accumulation. The attenuation of p53 induction was associated with increased 
MDM2 mRNA levels, Mdm2 protein binding to p53, and p53 ubiquitination. These 
observations indicated that the p53 protein was targeted for degradation, a process mediated 
by Mdm2. Thus, IL-6 inhibits p53 accumulation and thus function, which is important for the 
response to chemotherapeutic drugs. 
To examine the mechanism through which IL-6 might exert its action on reducing drug 
efficacy, I tested several inhibitors, including those against JAK, STAT3, PI3K and Akt, in 
order to block these factors downstream of IL-6 in the IL-6 signaling pathways. Through this 
approach, I could identify JAK and STAT3 as essential players in drug resistance mediated 
by IL-6. 
Furthermore, analyses of publicly available datasets also supported the findings above and 
revealed that amplification of the IL-6 receptor (IL-6R), STAT3 and MDM2 genes was more 
common in prostate tumors with unaltered TP53 gene than in tumors with altered TP53. The 
amplification of these genes also seemed to be more frequent in metastatic castration-resistant 
prostate cancer. The datasets further revealed higher IL-6R and MDM2 mRNA expression 
levels in prostate tumors with unaltered TP53 compared to tumors with putative driver TP53 
mutation. IL-6R, JAK and STAT3 mRNA levels also correlated with MDM2 mRNA levels 
in prostate tumors carrying unaltered TP53. All these findings suggest that there is selective 
pressure to inactivate p53 via IL-6, JAK, STAT3 and MDM2 in TP53 wild type prostate 
tumors, and that MDM2 may be upregulated by the IL-6/JAK/STAT3 pathway. The higher 
prevalence of IL-6R, STAT3 and MDM2 amplification in metastatic prostate tumors may 




Altogether, this study suggests another possible mechanism by which CAFs may confer drug 
resistance to tumor cells, and highlights IL-6 as a component in the tumor microenvironment 
with the ability to attenuate the drug-induced p53 response through the JAK/STAT3 signaling 
pathway. This negatively affects the treatment outcome. 
The CAF-mediated protective effect on cancer cell survival may be circumvented by 
targeting IL-6, or block the crosstalk between CAFs and cancer cells. Hence, the combination 
of targeted treatment with chemotherapeutic drugs may lead to improved and more effective 
cancer therapy. Several agents targeting the IL-6/JAK/STAT3 signaling pathways are being 
tested in clinical trials and evaluated in patients with different types of tumors, while some 
are currently in development. 
 
3.3 PAPER III 
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death 
The mutant p53-reactivating compound APR-246 is converted to the active product MQ, 
which readily reacts with cellular thiols 74,76. MQ also binds to cysteine residues in p53 76,79. 
Previous studies have demonstrated that APR-246 or MQ can deplete glutathione and inhibit 
the antioxidant systems 76,91-93. Tumor cells that exhibit high levels of glutathione are found to 
be more resistant to treatment with APR-246 94. Endogenous glutathione, as well as drugs 
conjugated to glutathione, are exported through the efflux pump MRP1 95. Given the roles of 
MRP1 in redox regulation and transporting glutathione-conjugated drugs, as well as 
association with drug resistance, we hypothesized that inhibition of MRP1 using the inhibitor 
MK-571 and trapping APR-246/MQ that conjugates to glutathione inside tumor cells would 
enhance therapeutic efficacy of APR-246. 
We tested the combination treatment of APR-246 with the MRP1 inhibitor MK-571 in 
several tumor cell lines and found that the combination treatment resulted in synergistic 
tumor cell death with a more pronounced effect in cells carrying mutant TP53. Combining 
APR-246 with Reversan, another MRP1 inhibitor, or with siRNAs against MRP1, gave 
similar results. We further confirmed our findings in oesophageal cancer cell xenograft 
mouse models and observed enhanced APR-246 anti-tumor activity in combination with 
MK-571. Both in vitro and in vivo experiments revealed that MRP1 blockade significantly 
enhanced APR-246-induced mutant p53 cancer cell death. 
The observed synergy was associated with increased intracellular drug accumulation. We 
analyzed drug content, specifically 14C accumulation, in various cell lines using radiolabelled 
14C-APR-246, where 14C is retained in MQ, in combination with MK-571, Reversan or 
MRP1 siRNAs. We found that MQ bound to glutathione (GS-MQ) was accumulated and also 
showed that the binding of MQ to glutathione is reversible. Thus, altogether these results 
reveal that MQ is exported via MRP1 and blocking MRP1 leads to the accumulation of MQ 
inside cells. GS-MQ is formed within cells and is remained trapped intracellularly upon 
MRP1 inhibition. Due to the reversibility of the conjugation formation, GS-MQ may serve as 
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a drug reservoir, increasing the availability of MQ for mutant p53 reactivation. This enhances 
sensitivity of mutant TP53-carrying cancer cells to APR-246.  
Furthermore, the cellular redox status was altered by the combination treatment. We detected 
an increase in intracellular cystine and cysteine, key building blocks for glutathione synthesis, 
as well as an elevated expression of xCT, the transporter of cystine, upon MRP1 inhibition by 
MK-571. After treatment with APR-246 and MK-571, the expression of xCT increased and 
the intracellular levels of GSH, GSSG and cysteine were decreased. Blocking xCT with the 
xCT inhibitor sulfasalazine (SSZ) or using siRNAs also resulted in increased 14C 
accumulation after 14C-APR-246 treatment, and increased APR-246-induced cell death. 
These results indicate that glutathione and cysteine availability determines drug accumulation 
and sensitivity to APR-246. The presence of mutant p53, cellular redox state, and drug 
accumulation together affect the cell death-inducing activity of APR-246. 
Overall, inhibition of MRP1 with MK-571 blocks drug export and leads to alterations in the 
cellular redox status, which then enhance the cell-death inducing activity of APR-246. This 
further verifies that cancer cells rely on glutathione to make themselves less sensitive to 
cancer therapy and drug-induced stress. Our results also suggest that combination treatment 
with APR-246 and inhibitors of MRP1 could improve clinical efficacy of the mutant p53-






4 CONCLUSIONS AND FUTURE PERSPECTIVES 
Cancer remains one of the leading causes of death globally. Despite immense amount of 
research in cancer biology and cancer drug discovery, many tumors still have poor prognosis. 
Therapy resistance is one of the major problems in anti-cancer therapy, and contributes to the 
high mortality rates. For this reason, it is essential to uncover molecular mechanisms 
governing cancer drug resistance. Development of novel strategies and targeted therapies to 
improve the outcome of treatment is critically needed. An increased understanding of the 
diverse molecular mechanisms that cancer cells depend on may provide opportunities for 
more efficient therapy by targeting disease-specific mechanisms or several pathways at the 
same time. Combination of targeted therapy with chemotherapy or other therapies may lead 
to more efficient treatment of cancer. 
CAFs, essential components of the tumor microenvironment, can protect cancer cells from 
therapy through several mechanisms. Therefore, they represent a potential therapeutic target 
for the treatment of cancer. In the paper I and II, chemoresistance-associated molecules, 
produced by CAFs, have been identified. My studies revealed that glutathione and IL-6 could 
promote chemoresistance in prostate cancer cells carrying wild type p53 through different 
mechanisms. Glutathione shields cancer cells from drug-induced oxidative stress and DNA 
damage, as it also decreased drug accumulation, while IL-6 attenuates the drug-induced p53 
response through STAT3 and MDM2. Depletion of these molecules, or targeting the 
interaction between stroma and cancer cells, may therefore decrease or prevent therapy 
resistance in cancer. Thus, the co-targeting of cancer cells and their microenvironment is 
likely to be a fruitful strategy for improved cancer treatment. 
Other soluble factors than those discussed in paper I and II can presumably increase drug 
resistance, given that CAFs secrete a vast repertoire of soluble factors, as shown in paper II. 
Thus, the identification of novel molecules linked to resistance and poor prognosis may 
provide novel clinical prognostic markers and open novel avenues for more efficient therapy 
for different types of cancer. 
Accordingly, the findings from paper I and II are in line with other studies depicting a 
critical role of the tumor microenvironment, specifically CAFs, in cancer progression and 
development. The papers thus confirm that CAFs can have a significant impact on the 
therapeutic response and extend current understanding by identifying specific molecular 
mechanisms. 
Paper III demonstrates that inhibition of the MRP1 drug efflux pump can enhance sensitivity 
of mutant TP53-carrying cancer cells to APR-246, as combination treatment of APR-246 
with MRP1 inhibitors resulted in synergistic cancer cell death. This was associated with 
altered cellular redox status and increased intracellular MQ, the active product of APR-246, 
conjugated to glutathione. The reversibility of MQ conjugation may lead to increased 
availability of MQ for targeting mutant p53. Our findings revealed that several players are 
involved in determining sensitivity to APR-246 treatment. The presence of mutant p53, redox 
state in the cells and drug accumulation together affect the cell death-inducing activity of 
APR-246, which could be potentiated by MRP1 inhibition. Hence, this study also highlights 
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the impact of the cellular redox status and glutathione content on the cancer cell survival and 
response to mutant p53-targeted therapy. 
The studies in this thesis have revealed several putative drug targets, including glutathione 
and redox signaling molecules, the IL-6/JAK/STAT3 signaling pathway, and the MRP1 
transporter. Blocking these resistance-promoting pathways may greatly enhance the efficacy 
of chemotherapy and other types of therapy. High expressions of enzymes involved in 
glutathione synthesis, IL-6, STAT3, MDM2, mutant p53, and MRP1 in tumors may also 
represent useful predictive markers of drug resistance. Since non-cancerous cells of the tumor 
microenvironment are genetically more stable than tumor cells, they represent a favorable 
therapeutic target with lower risk of drug resistance. Hence, targeting the tumor 
microenvironment has huge potential for future cancer therapy.  
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